Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants - Anraku, Yuki; Kita, Shunsuke; Onodera, Taishi; Sato, Akihiko; Tadokoro, Takashi; Ito, Shiori; Adachi, Yu; Kotaki, Ryutaro; Suzuki, Tateki; Sasaki, Jiei; Shiwa-Sudo, Nozomi; Iwata-Yoshikawa, Naoko; et al. (Communications biology, 2025)
Keywords: 631/326/596/4130; 631/535/1258/1259; 631/535/1266; 631/61/51/2318; 82/1; 82/103; ACE2; Angiotensin-Converting Enzyme 2; Animals; Antibodies; Antibodies, Neutralizing - chemistry; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - chemistry; Antibodies, Viral - immunology; Antibodies, Viral - therapeutic use; Biomedical and Life Sciences; COVID-19; COVID-19 - immunology; COVID-19 - therapy; COVID-19 - virology; COVID-19 Drug Treatment; Cricetinae; Cryoelectron Microscopy; Humans; Life Sciences; Medical treatment; Mesocricetus; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - chemistry; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Structure-function relationships